CTOs on the Move


 
Inari embraces diversity in every aspect of our business to drive innovation and help build a new food system. Our technology matches the complexity of nature to transform seed using predictive design and multiplex gene editing – unlocking the full potential through our SEEDesign™ platform. The result is step-change products that lead to more productive acres and a more sustainable future for the food system.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.inari.com
  • One Kendall Square Building 600/700 Suite 7-501
    Cambridge, MA USA 02139
  • Phone: 774.489.5343

Executives

Name Title Contact Details
Rania Khalaf
Chief Information and Data Officer Profile

Funding

Inari raised $40M on 08/09/2018
Inari raised $89M on 08/01/2019
Inari raised $45M on 04/22/2020
Inari raised $208M on 05/12/2021

Similar Companies

Portage Biotech

Portage is a unique entity in the world of biotechnology, catalyzing R&D to produce more quality clinical programs and maximize potential returns.

Ann Arbor Bio Research / MicroDose Life Sciences

Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Using artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, we are accelerating the discovery of proteins...

Therapure

Therapure is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gritstone Bio

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.

BioBuzz

Biotech and Life Science News, Jobs, and Events for the BioHealth Capital Region - Maryland, D.C., and Virginia. BioBuzz: Be More Connected.